Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Biotechnology

Healthcare
$95.05 +0.77%

+$0.42 today

Market cap
$7.47B
Beta
0.12
P/E (TTM)
57.2
EPS (TTM)
$0.95
52W Low $26.27High $59.87

Volume 0.33M

Average 0.66M

KNSA Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA

Retained Earnings · Q2 FY2026 · quarter ended Jun 2026

Retained earnings remains negative

Q2 FY2026 retained earnings was -$414.11M, compared with -$494.77M a year earlier.

Context

  • Retained earnings amounted to 46.2% of total assets at the end of Q2 FY2026, down 28.6 pp from a year earlier.
  • Retained earnings grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps rising in the next quarterly balance sheet after a +16.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$414.11M+5.8% QoQ
Last fiscal yearDec 2025
-$462.14M+11.3% YoY
Year agoJun 2025
-$494.77M+16.3% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.3%——
1 year+11.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(462.14M) USD
Year-over-year change
+11.3%

Retained Earnings vs competitors

How KNSA compares with its peers on the latest reported figures

  • KNSA's Jun 2026 retained earnings of -$414.11M is the 3rd highest of the 10 companies compared; the peer median is -$630.13M.
  • Its year-over-year change of +16.3% is the 2nd highest of 10, against a peer median of -22.1%.
  • Retained earnings amounts to 46.2% of total assets for KNSA, versus a peer median of 120.8%.
KNSA Competitors Peer median
Retained Earnings for KNSA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PHARPharming Group N.V.Mar 2026-$281.46M +3.9%—57.5%
ORKAOruka Therapeutics, Inc.Sep 2026-$312.15M -95.6%—25.4%
KNSAKiniksa Pharmaceuticals, Ltd.Jun 2026-$414.11M +16.3%—46.2%
DNTHDianthus Therapeutics, Inc.Jun 2026-$427.78M -81.6%—35.3%
AVTXAvalo Therapeutics, Inc.Mar 2026-$468.15M -22.1%—468.7%
NRIXNurix Therapeutics, Inc.Aug 2026-$630.13M +31.9%—52.7%
ANABAnaptysBio, Inc.Mar 2026-$825.44M -3.4%—250.4%
ACRSAclaris Therapeutics, Inc.Mar 2026-$987.61M -7.6%—497.0%
SYRESpyre Therapeutics, Inc.Sep 2026-$1.33B -24.8%—120.8%
IMVTImmunovant, Inc.Sep 2026-$2B -34.2%—262.2%
Peer median (excluding KNSA) -$630.13M-22.1%—120.8%

Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents122.47M122.72M107.95M183.58M165.6M
Short-term Investments59.73M67.89M98.42M60.05M248.48M
Net Receivables3.99M20.32M21.27M41.72M15.59M
Inventory3.68M21.6M31.12M26.36M54.9M
Other Current Assets010.54M17.54M20.08M42.61M
Total Current Assets196.45M243.06M276.3M331.8M527.18M
Property, Plant & Equipment (Net)8.38M7.04M12.67M11.04M11.75M
Goodwill00000
Intangible Assets19.25M18.25M17.25M16.25M15.25M
Long-term Investments00000
Tax Assets0185.5M219.28M211.15M198.15M
Other Non-current Assets8.72M5.82M827K10.32M11.31M
Total Non-current Assets36.35M216.61M250.03M248.75M236.46M
Total Assets232.8M459.67M526.32M580.55M763.63M
Account Payables1.87M7.9M8.25M2.04M2.03M
Short-term Debt00002.99M
Tax Payables00000
Deferred Revenue00307K031.81M
Other Current Liabilities1.54M16.97M36.91M33.12M102.36M
Total Current Liabilities44.82M47.07M63.67M100.62M139.18M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)012M11.95M31.81M31.81M
Other Non-current Liabilities270K1.84M1.86M1.82M18.52M
Total Non-current Liabilities2.94M16.46M23.82M41.5M56.84M
Total Liabilities47.76M63.52M87.48M142.12M196.03M
Common Stock18K19K20K20K21K
Retained Earnings(675.4M)(492.03M)(477.95M)(521.14M)(462.14M)
Accumulated OCI(66K)44K6K(163K)(25K)
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity185.04M396.15M438.84M438.44M567.61M
Total Debt6.05M5.92M12.26M9.86M9.5M
Net Debt(116.42M)(116.8M)(95.7M)(173.73M)(156.1M)

Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Intrinsic Alpha fair value

Locked

Current Price

$95.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.